↓ Skip to main content

Laquinimod for multiple sclerosis.

Overview of attention for article published in Cochrane database of systematic reviews, August 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

1 blog
1 policy source
5 tweeters
4 Wikipedia pages


3 Dimensions

Readers on

102 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Laquinimod for multiple sclerosis.
Published in
Cochrane database of systematic reviews, August 2013
DOI 10.1002/14651858.cd010475.pub2
Pubmed ID

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S, He, Dian, Han, Kai, Gao, Xiangdong, Dong, Shuai, Chu, Lan, Feng, ZhanHui, Wu, Shan, Dian He, Kai Han, Xiangdong Gao, Shuai Dong, Lan Chu, ZhanHui Feng, Shan Wu


Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not all MS patients respond adequately to currently available disease-modifying drugs (DMDs). Alternative MS treatments with new modes of action are required to expand the current options for disease-modifying therapies (DMTs) and to aim for freedom from relapses, inflammatory lesions, disability progression and neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection and is a potentially promising new oral DMD in the treatment of relapsing MS.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
South Africa 1 <1%
Brazil 1 <1%
Unknown 99 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 23%
Student > Ph. D. Student 17 17%
Researcher 11 11%
Student > Bachelor 10 10%
Student > Postgraduate 6 6%
Other 18 18%
Unknown 17 17%
Readers by discipline Count As %
Medicine and Dentistry 43 42%
Nursing and Health Professions 13 13%
Biochemistry, Genetics and Molecular Biology 5 5%
Social Sciences 5 5%
Psychology 4 4%
Other 9 9%
Unknown 23 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2020.
All research outputs
of 15,827,240 outputs
Outputs from Cochrane database of systematic reviews
of 11,293 outputs
Outputs of similar age
of 160,453 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 128 outputs
Altmetric has tracked 15,827,240 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,293 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.5. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 128 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.